2. Academic Validation
  3. Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers

Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers

  • Cancer Res Commun. 2025 Jan 1;5(1):24-38. doi: 10.1158/2767-9764.CRC-24-0484.
Mariko Sasaki 1,  Daiki Kato 2,  Hiroshi Yoshida 3,  Takafumi Shimizu 2,  Hideaki Ogiwara 1
Affiliations

Affiliations

  • 1 Division of Cancer Therapeutics, National Cancer Center Research Institute, Tokyo, Japan.
  • 2 Cancer Research Unit, Sumitomo Pharma Co., Ltd, Osaka, Japan.
  • 3 Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
PMID: 39625239 DOI: 10.1158/2767-9764.CRC-24-0484
Abstract

In this study, we clarified that the cBAF subcomplex is deficient in the SWI/SNF complex, resulting in dependency on the CBP/p300 paralog pair. Simultaneous inhibitors of the CBP/p300 paralog pair show promise for cBAF-deficient lung Cancer, as well as rare cancers such as malignant rhabdoid tumors, epithelioid sarcomas, and synovial sarcomas.

Figures
Products